Telehealth use in patients with type 2 diabetes in Australian general practice during the COVID-19 pandemic: a retrospective cohort study

The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown. To evaluate the upta...

Full description

Saved in:
Bibliographic Details
Published inBJGP open Vol. 6; no. 3; p. BJGPO.2021.0200
Main Authors Imai, Chisato, Thomas, Judith, Hardie, Rae-Anne, Pearce, Christopher, Badrick, Tony, Georgiou, Andrew
Format Journal Article
LanguageEnglish
Published England Royal College of General Practitioners 01.09.2022
Subjects
Online AccessGet full text
ISSN2398-3795
2398-3795
DOI10.3399/BJGPO.2021.0200

Cover

Loading…
Abstract The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown. To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations. This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included. Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth. Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only. Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations.
AbstractList The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown. To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations. This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included. Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth. Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only. Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations.
The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown.BACKGROUNDThe Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown.To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations.AIMTo evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations.This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included.DESIGN & SETTINGThis exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included.Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth.METHODTelehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth.Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only.RESULTSOf 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only.Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations.CONCLUSIONTelehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations.
Background: The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown. Aim: To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations. Design & setting: This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019–February 2020 was compared with a pandemic period from March 2020–February 2021. Patients diagnosed with T2DM before March 2018 were included. Method: Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth. Results: Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only. Conclusion: Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations.
Author Pearce, Christopher
Imai, Chisato
Georgiou, Andrew
Badrick, Tony
Thomas, Judith
Hardie, Rae-Anne
Author_xml – sequence: 1
  givenname: Chisato
  orcidid: 0000-0002-0080-1487
  surname: Imai
  fullname: Imai, Chisato
– sequence: 2
  givenname: Judith
  orcidid: 0000-0002-0715-9124
  surname: Thomas
  fullname: Thomas, Judith
– sequence: 3
  givenname: Rae-Anne
  orcidid: 0000-0003-4868-4045
  surname: Hardie
  fullname: Hardie, Rae-Anne
– sequence: 4
  givenname: Christopher
  orcidid: 0000-0001-5371-8196
  surname: Pearce
  fullname: Pearce, Christopher
– sequence: 5
  givenname: Tony
  orcidid: 0000-0003-4846-9134
  surname: Badrick
  fullname: Badrick, Tony
– sequence: 6
  givenname: Andrew
  orcidid: 0000-0002-7619-3668
  surname: Georgiou
  fullname: Georgiou, Andrew
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35640964$$D View this record in MEDLINE/PubMed
BookMark eNp1Uk1v1DAQtVARLaVnbshHLtn6K07MAaksUBZVWg6Fq-U4k11X2TjYTtH-BP41TrdULRKyrBmN37zxzLyX6GjwAyD0mpIF50qdf_h6-W29YITRBWGEPEMnjKu64JUqjx75x-gsxhtCCFVUCiFeoGNeSkGUFCfo9zX0sAXTpy2eImA34NEkB0OK-JfLwbQfATPcOtNAgjgDLqaYgumdGfAGBsguHoOxyVnA7RTcsMFpC3i5_rH6WFCVCYcWds6-wwYHSMHHETL6FrD1Wx8Sjmlq96_Q8870Ec7u7Sn6_vnT9fJLcbW-XC0vrgorSpWKqjGdknXTGmmhpZKXVcuhYh1ISkhVq1rWlehqqjpLaso40JJlI8qOg-Kcn6LVgbf15kaPwe1M2GtvnL4L-LDRJuReetCsqQC4kIITlW_XEKFq1nayoo3qSpK53h-4xqnZQWvz2PI0npA-fRncVm_8rc4dkErOBG_vCYL_OUFMeueihb43A_gpaiYrxudTZ-ibx7UeivzdZQacHwA2TzgG6B4glOhZMPpOMHoWjJ4FkzPKfzKsS3n7fv6s6_-b9wfU_8RW
CitedBy_id crossref_primary_10_2196_42607
crossref_primary_10_56294_saludcyt2024750
crossref_primary_10_3399_BJGPO_2022_0120
crossref_primary_10_2196_42753
crossref_primary_10_1186_s41043_023_00418_x
crossref_primary_10_1111_jocn_16805
crossref_primary_10_3399_BJGPO_2022_0117
Cites_doi 10.1016/j.mpmed.2018.10.002
10.1186/s12874-018-0519-5
10.1089/tmj.2018.0128
10.1111/imj.15441
10.1177/1357633X20985763
10.1001/jama.280.19.1690
10.2522/ptj.20080020
10.1016/j.ijmedinf.2020.104189
10.1111/jdi.13546
10.1097/MD.0000000000000312
10.1177/1932296820947094
10.3389/fpubh.2021.648009
10.1016/j.ijmedinf.2021.104483
10.3390/diabetology2010001
10.1016/j.diabres.2020.108298
10.1136/bmjhci-2019-100009
10.1177/0036933020946336
10.1159/000509000
10.1210/jendso/bvab048.710
10.1016/j.ijmedinf.2018.07.007
10.3904/kjim.2020.464
ContentType Journal Article
Copyright Copyright © 2022, The Authors.
Copyright © 2022, The Authors 2022
Copyright_xml – notice: Copyright © 2022, The Authors.
– notice: Copyright © 2022, The Authors 2022
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3399/BJGPO.2021.0200
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2398-3795
ExternalDocumentID oai_doaj_org_article_2b7ee3464309430fb04982df671b9f50
PMC9680760
35640964
10_3399_BJGPO_2021_0200
Genre Journal Article
GroupedDBID 5VS
AAYXX
ACDUE
ADBBV
AIJKH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
CITATION
EBS
EIHBH
GROUPED_DOAJ
HYE
M~E
OK1
RPM
NPM
7X8
5PM
ID FETCH-LOGICAL-c459t-7baf968bda6ced16357d3e72fe610078986874f819fc08123e15212345f3e9333
IEDL.DBID DOA
ISSN 2398-3795
IngestDate Wed Aug 27 01:27:33 EDT 2025
Thu Aug 21 18:39:37 EDT 2025
Fri Jul 11 10:32:05 EDT 2025
Thu Apr 03 06:59:36 EDT 2025
Tue Jul 01 02:53:00 EDT 2025
Thu Apr 24 23:11:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords COVID-19
telemedicine
diabetes mellitus, type 2
general practice
Language English
License Copyright © 2022, The Authors.
This article is Open Access: CC BY license (https://creativecommons.org/licenses/by/4.0/)
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-7baf968bda6ced16357d3e72fe610078986874f819fc08123e15212345f3e9333
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0080-1487
0000-0002-7619-3668
0000-0002-0715-9124
0000-0001-5371-8196
0000-0003-4868-4045
0000-0003-4846-9134
OpenAccessLink https://doaj.org/article/2b7ee3464309430fb04982df671b9f50
PMID 35640964
PQID 2672323238
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_2b7ee3464309430fb04982df671b9f50
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9680760
proquest_miscellaneous_2672323238
pubmed_primary_35640964
crossref_primary_10_3399_BJGPO_2021_0200
crossref_citationtrail_10_3399_BJGPO_2021_0200
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-01
PublicationDateYYYYMMDD 2022-09-01
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle BJGP open
PublicationTitleAlternate BJGP Open
PublicationYear 2022
Publisher Royal College of General Practitioners
Publisher_xml – name: Royal College of General Practitioners
References 2022092817501035000_6.3.BJGPO.2021.0200.21
2022092817501035000_6.3.BJGPO.2021.0200.20
2022092817501035000_6.3.BJGPO.2021.0200.25
2022092817501035000_6.3.BJGPO.2021.0200.24
2022092817501035000_6.3.BJGPO.2021.0200.23
2022092817501035000_6.3.BJGPO.2021.0200.22
2022092817501035000_6.3.BJGPO.2021.0200.9
2022092817501035000_6.3.BJGPO.2021.0200.18
2022092817501035000_6.3.BJGPO.2021.0200.8
2022092817501035000_6.3.BJGPO.2021.0200.17
2022092817501035000_6.3.BJGPO.2021.0200.16
2022092817501035000_6.3.BJGPO.2021.0200.15
2022092817501035000_6.3.BJGPO.2021.0200.5
2022092817501035000_6.3.BJGPO.2021.0200.4
2022092817501035000_6.3.BJGPO.2021.0200.7
2022092817501035000_6.3.BJGPO.2021.0200.6
2022092817501035000_6.3.BJGPO.2021.0200.19
2022092817501035000_6.3.BJGPO.2021.0200.1
2022092817501035000_6.3.BJGPO.2021.0200.3
2022092817501035000_6.3.BJGPO.2021.0200.2
2022092817501035000_6.3.BJGPO.2021.0200.10
2022092817501035000_6.3.BJGPO.2021.0200.31
2022092817501035000_6.3.BJGPO.2021.0200.30
2022092817501035000_6.3.BJGPO.2021.0200.14
2022092817501035000_6.3.BJGPO.2021.0200.13
2022092817501035000_6.3.BJGPO.2021.0200.12
2022092817501035000_6.3.BJGPO.2021.0200.11
2022092817501035000_6.3.BJGPO.2021.0200.29
2022092817501035000_6.3.BJGPO.2021.0200.28
2022092817501035000_6.3.BJGPO.2021.0200.27
2022092817501035000_6.3.BJGPO.2021.0200.26
References_xml – ident: 2022092817501035000_6.3.BJGPO.2021.0200.3
  doi: 10.1016/j.mpmed.2018.10.002
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.22
  doi: 10.1186/s12874-018-0519-5
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.30
  doi: 10.1089/tmj.2018.0128
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.8
  doi: 10.1111/imj.15441
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.11
  doi: 10.1177/1357633X20985763
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.4
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.23
  doi: 10.1001/jama.280.19.1690
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.19
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.17
  doi: 10.2522/ptj.20080020
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.26
  doi: 10.1016/j.ijmedinf.2020.104189
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.10
  doi: 10.1111/jdi.13546
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.29
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.31
  doi: 10.1097/MD.0000000000000312
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.6
  doi: 10.1177/1932296820947094
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.27
  doi: 10.3389/fpubh.2021.648009
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.21
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.25
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.13
  doi: 10.1016/j.ijmedinf.2021.104483
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.2
  doi: 10.3390/diabetology2010001
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.18
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.16
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.5
  doi: 10.1016/j.diabres.2020.108298
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.14
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.15
  doi: 10.1136/bmjhci-2019-100009
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.1
  doi: 10.1177/0036933020946336
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.28
  doi: 10.1159/000509000
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.12
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.7
  doi: 10.1210/jendso/bvab048.710
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.24
  doi: 10.1016/j.ijmedinf.2018.07.007
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.20
– ident: 2022092817501035000_6.3.BJGPO.2021.0200.9
  doi: 10.3904/kjim.2020.464
SSID ssj0001916444
Score 2.2486746
Snippet The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the...
Background: The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage BJGPO.2021.0200
SubjectTerms covid-19
diabetes mellitus, type 2
general practice
telemedicine
Title Telehealth use in patients with type 2 diabetes in Australian general practice during the COVID-19 pandemic: a retrospective cohort study
URI https://www.ncbi.nlm.nih.gov/pubmed/35640964
https://www.proquest.com/docview/2672323238
https://pubmed.ncbi.nlm.nih.gov/PMC9680760
https://doaj.org/article/2b7ee3464309430fb04982df671b9f50
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQT1wQiBbCRzVIPXAJ3diO7fRGC6VUgnJoUW9W7NhQqcqi3eyP6L9mxk6WXQTignJLbMfyjDVvxjPPjB2gkYtBtabUwvMSTYAr2zhzpZh1vhJ-1jYp3vHpszq7kufX9fXGVV-UE5bpgfPCHXKnQxASx6QcuFl0CGkN76LSlWti9tbR5m04Uym6gqhHSpm5fAQa4cPj8w9fLtAf5MTRSfVsG2YosfX_CWL-nim5YXpOH7IHI2aEt3muj9i90D9md5doMHIVI6yWAW56GDlSl0DBVaDgKnCYgqvU4FdgA75lummYqqQg1ysC4kE4ufj68V1ZNThgn5Lnj6CFRRgW86kuE-he3cUAiZx2l12dvr88OSvHexVKL-tmKLVrY6OM61rlQ1cRI10nguYoNMqZMI1RRsuIWCF6RAxchCpV-Mo6itAIIfbYTj_vw1MGvhZd28kKO9USwYDrjDMyeonyb6TTBXszLbP1I-k43X1xa9H5ILnYJBdLcrEkl4K9Xnf4kfk2_t70mOS2bkZE2ekFqo8d1cf-S30K9mqSusWNRaclbR_mq6XlSiPaxMcU7EnWgvWvRK3QL1ayYHpLP7bmsv2lv_meyLtx4ekw9Nn_mPxzdp9TNUZKeXvBdobFKrxEjDS4_bQdfgL2ng4H
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Telehealth+use+in+patients+with+type+2+diabetes+in+Australian+general+practice+during+the+COVID-19+pandemic%3A+a+retrospective+cohort+study&rft.jtitle=BJGP+open&rft.au=Imai%2C+Chisato&rft.au=Thomas%2C+Judith&rft.au=Hardie%2C+Rae-Anne&rft.au=Pearce%2C+Christopher&rft.date=2022-09-01&rft.issn=2398-3795&rft.eissn=2398-3795&rft.volume=6&rft.issue=3&rft_id=info:doi/10.3399%2FBJGPO.2021.0200&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2398-3795&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2398-3795&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2398-3795&client=summon